Moody National Bank Trust Division Has $7.63 Million Position in Pfizer Inc. (NYSE:PFE)

Moody National Bank Trust Division lifted its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 0.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 148,830 shares of the biopharmaceutical company’s stock after purchasing an additional 653 shares during the period. Pfizer makes up approximately 0.7% of Moody National Bank Trust Division’s investment portfolio, making the stock its 16th biggest holding. Moody National Bank Trust Division’s holdings in Pfizer were worth $7,626,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Karp Capital Management Corp bought a new position in shares of Pfizer during the third quarter worth $27,000. Worth Asset Management LLC acquired a new stake in Pfizer during the 1st quarter worth $29,000. Delos Wealth Advisors LLC lifted its holdings in Pfizer by 100.0% during the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 400 shares in the last quarter. Legend Financial Advisors Inc. acquired a new position in Pfizer in the third quarter valued at about $42,000. Finally, JDM Financial Group LLC bought a new stake in shares of Pfizer in the fourth quarter worth about $43,000. Institutional investors own 67.62% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $40.10 on Friday. The firm’s fifty day moving average price is $43.26 and its two-hundred day moving average price is $46.03. Pfizer Inc. has a 1 year low of $39.23 and a 1 year high of $56.32. The firm has a market capitalization of $225.33 billion, a P/E ratio of 7.32, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34.

Pfizer (NYSE:PFE – Get Rating) last issued its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. The business had revenue of $24.30 billion during the quarter, compared to the consensus estimate of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. Pfizer’s revenue was up 1.9% on a year-over-year basis. During the same period last year, the business posted $1.08 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 3.3 EPS for the current year.

Analyst Upgrades and Downgrades

PFE has been the topic of several recent analyst reports. Barclays cut their price objective on Pfizer from $49.00 to $44.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 1st. Bank of America cut shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price target for the company. in a report on Wednesday, January 4th. JPMorgan Chase & Co. set a $45.00 price objective on shares of Pfizer in a report on Monday, February 27th. Berenberg Bank set a $40.00 target price on shares of Pfizer in a research note on Tuesday, February 7th. Finally, Wells Fargo & Company dropped their price target on Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Friday. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $50.38.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.